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Aim: To study the expression of adhesion markers (E-cadherin, β-catenin and vimentin) associated with epithelial-mesenchymal 
transition (EMT) and their role in progression of endometrial carcinoma (EC). Materials and Methods: Expression of E-cadherin, 
β-catenin and vimentin was studied immunohistochemically in the samples of surgical material of 55 EC patients stage I–III. The 
proliferation index was determined by flow cytometry. Results: In the group of vimentin-negative EC, tumors of low differentia-
tion grade and deep invasion in myometrium as well as high expression of E-cadherin and β-catenin prevailed compared with the 
cases with high expression of vimentin. In addition, in EC with high expression of vimentin, an increase in the number of cells 
with expression of E-cadherin in the cytoplasm (78.9 ± 3.6%) and β-catenin with cytoplasmic-nuclear localization (73.7 ± 3.2%) 
was observed compared with these indices in vimentin-negative tumors (45.4 ± 4.2%, p < 0.001 and 54.5 ± 2.6%, respectively, 
p < 0.005), which may indicate EMT-associated changes in EC with high expression of vimentin. Conclusions: The progression 
of the endometrioid carcinoma may occur in the setting of various molecular changes, in particular, with decreased expression 
of E-cadherin and β-catenin and high expression of vimentin, or in the absence of vimentin, utilizing other mechanisms of regula-
tion of proliferative and metastatic potential.
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According to available literature, endometrial can-
cer is predominantly diagnosed at early stages (80% 
at stage I) and, as a rule, has a relatively favorable 
course with a five-year survival of over 95%. How-
ever, the five-year survival rates of such patients are 
much lower in the presence of metastases in regional 
lymph nodes or relapse of the disease (respectively, 
68% and 17%) [1]. In a number of cases, this is due 
to the low effectiveness of therapeutic measures that 
do not take into account the molecular mechanisms 
of cancer progression.
It is known that the biological features of endome-
trial carcinoma (EC) are formed under the influence 
of a number of different factors, such as the hormonal 
background in which tumors have developed, changes 
in the functioning of oncogenes and suppressor 
genes, and the composition of the tumor microenviron-
ment. All this contributes to the emergence of genome 
instability and the accumulation of genetic alterations 
in cancer cells [2–5].
To some extent, the progression of malignant 
neoplasms (increased proliferative activity, invasive, 
angiogenic and metastatic potential) depends on the 
changes in the expression of molecules that provide 
intercellular contacts. The loss of adhesive properties 
by tumor cells contributes to their increased mobility 
and, as a consequence, penetration into surrounding 
tissues, blood and lymphatic vessels [6]. Recent studies 
have shown that the migration of neoplastic cells dur-
ing tumor progression can be the result of consistent 
molecular changes and a complex of morphological 
alterations that are accompanied by the destruction 
of the basement membrane of cancer cells and the loss 
of the polar orientation of their nuclei, while epithelial 
cells may acquire mesenchymal-like morphology. This 
phenomenon was called epithelial-mesenchymal tran-
sition (EMT) and, according to Qin et al. [7] is a strategy 
of immune rescue, adaptation of cancer cells to in-
crease their chances of survival in mesenchymal tissues 
by mimicry. In this case, abnormal epithelial cells not 
only lose the expression of epithelial markers, but they 
may acquire expression of an unusual protein for epi-
thelial cells, a marker of mesenchymal cells — vimentin.
The role of vimentin in determining the malignancy 
of solid tumors of various genesis has not been clari-
fied yet [8], however, the appearance of this protein 
in EC cells is associated with tumor invasiveness and 
metastasis [9]. In contrast, in endometrial serous 
carcinomas, which are more aggressive tumors with 
an unfavorable course of the disease, vimentin ex-
pression is usually absent or is significantly lower than 
in endometrioid type EC [10, 11]. 
The main proteins that provide stable intercellular 
contacts between epithelial cells and inhibit their 
mobility are cadherins and catenins, in particular E-
cadherin and β-catenin. E-cadherin belongs to the 
family of transmembrane glycoproteins being one 
of the key cadherins that provides Ca2+-dependent 
homophilic adhesion in epithelial tissues by the forma-
tion of transdimers in two adjacent cells via the inter-
action of extracellular domains [12]. Its intracellular 
domain is bound to a number of proteins and, in the 
first place, with β-catenin, which, apart from E-cad-
herin, binds with α-catenin and actin microfilaments, 
providing dense intercellular contacts [12, 13]. The 
interaction of E-cadherin with β-catenin is regulated 
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by the level of serine and threonine phosphorylation 
in β-catenin [14–16].
In most epithelial neoplasias, including EC, there 
is a decrease in the expression of E-cadherin, including 
hypermethylation of the promoter of its gene — CDH1, 
sometimes with gene mutations or deletions on the 3rd 
chromosome [17, 18]. In addition, the functional loss 
of E-cadherin may be due to the activation of transcrip-
tion factors Snail1 and Snail2 or ZEB1 and ZEB2, which 
suppress the expression of the CDH1 gene [14, 19]. 
As a result, the destruction of E-cadherin/β-catenin 
complex and intercellular bonds occurs, E-cadherin 
is translocated into the cytoplasm, and β-catenin is re-
leased and accumulated in the cytoplasm followed by its 
translocation into the nucleus [13, 14].
The aim of the study was to analyze the features of the 
expression of adhesion markers E-cadherin, β-catenin 
and vimentin and their role in progression of ECs.
MATERIALS AND METHODS
The study was conducted on the samples 
of surgical material of 55 EC patients (47 with 
stage I and II EC and 8 with stage III EC according 
to TNM and FIGO classifications). The patients did not 
receive preoperative therapy, their age ranged from 
32 to 73 years (average 58.9 ± 6.5 years). All patients 
were treated at the Department of Oncogynecology 
of the National Cancer Institute of the Ministry of Health 
of Ukraine from 2014 to 2017 and provided informed 
consent on the use of their biological material for sci-
entific research. Morphological diagnosis was verified 
on histological preparations stained with hematoxylin 
and eosin. The differentiation grade of tumors was de-
termined according to WHO criteria (2014) [20].
Immunohistochemical (IHC) detection of E-cadherin, 
β-catenin and vimentin was performed on deparaffined 
sections, using MoAbs to E-cadherin (clone NСН-38), 
β-catenin (clone β-catenin-1) (DakoCytomation, Den-
mark), vimentin (clone V9) (Diagnostic BioSystems, the 
Netherlands). In each slide 700–1000 cells were analyzed. 
The results of the IHC reaction were evaluated by the semi-
quantitative method counting the number of stained cells 
and the intensity of the reaction (H-score, points). The 
analysis took into account the number of cells (%) with 
the membrane-cytoplasmic localization of E-cadherin and 
cytoplasmic-nuclear — of β-catenin [9, 21].
The proliferation index (PI, %, i.e. the number of cells 
in the S + G2/M phases of the mitotic cycle) was deter-
mined using the flow cytometry method after staining 
cells with fluorochrome — propidium iodide [22]. The 
studies were conducted on a flow cytometric analyzer 
EPICS-XL (Beckman Coulter, USA).
To objectivize the evaluation of the expression 
of the biomolecular markers examined, we deter-
mined the median (Me) of the number and intensity 
of stained cells (H-score) or the proliferative poten-
tial — MePI. The values of all indices less than Me were 
considered low, and above Me — high.
Statistical data were processed using Statis-
tica 8.0 software package (StatSoft, Inc.) by non-
parametric Mann — Whitney U Test. Differences 
at p < 0.05 were considered significant.
RESULTS 
According to morphological analysis of histologi-
cal preparations, all patients had endometrioid form 
of EC of high (7.2%), moderate (41.8%) and low 
(50.9%) differentiation grade. 40% of tumors had 
minor invasion in myometrium (< ½) and 60% invaded 
by > ½ of myometrium.
According to the results of flow cytometry, it was 
found that while S + G2/M ratio varied from 8.5% 
to 48.7%, PI was 27.6 ± 4.3%, with Me = 25.4%.
The results of IHC study showed that positive ex-
pression of E-cadherin was observed in 78.2% of EC, 
β-catenin — 100% and vimentin in 74.5%. The protein 
product was detected diffusely, or in separate sections 
of the tumor (Fig. 1).
At that, a significant variation in the expression of the 
investigated proteins was observed: individual variations 
in the expression of E-cadherin were 14.6–190.6 points 
(66.3 ± 5.3 points on the average), β-catenine — 
55.0–237.4 points (155.0 ± 6.4 points on the average), 
vimentin — 15.4–242.1 points (53.4 ± 4.8 points on the 
average). Me values of the expression of these markers 
were 51.5, 152.5 and 41.6 points, respectively.
Comparison of expression of EMT-associated mo-
lecular markers in EC of different grade showed that 
the expression of E-cadherin was higher, and vimentin 
lower (significantly or at the level of tendency) in low-
differentiated tumors than in tumors deeply invaded 
the myometrium (Table 1).
Table 1. Expression of E-cadherin, β-catenin and vimentin in EC related 
to clinical and pathological characteristics of tumors
Parameter Expression of markers of EM transition, H-score, pointsE-cadherin β-catenin Vimentin 
M ± m
Min–Max
66.3 ± 5.3 
14.6–190.6
155.0 ± 6.4 
55.0–237.4
53.4 ± 4.8 
15.4–242.1
PI:
< Ме (25.4%)
> Ме (25.4%)
52.9 ± 4.2
93.9 ± 4.7**
159.9 ± 6.1
148.3 ± 6.2
52.7 ± 3.8
57.1 ± 4.9
Differentiation grade: 
G1
G2
G3
49.7 ± 5.4
77.1 ± 6.0*
75.6 ± 6.1*
190.0 ± 9.3
150.0 ± 8.5*
151.9 ± 8.9*
99.1 ± 8.4
56.3 ± 4.6*
39.1 ± 3.3**
Depth of tumor inva-
sion into myometrium:
< ½
> ½
69.1 ± 4.0
83.3 ± 5.0
161.0 ± 9.3
150.7 ± 9.7
68.4 ± 4.1
42.5 ± 3.2**
Stage:
І
ІІ
ІІІ
73.6 ± 4.1
72.3 ± 4.6
92.0 ± 5.7
149.6 ± 7.7
158.4 ± 10.2
171.3 ± 9.6
66.0 ± 3.4
40.5 ± 5.7
14.4 ± 4.4**
Notes: E-cadherin: *p < 0.05 compared with G1 tumors; **p <0.01 com-
pared with PI < Me; β-catenin: *p < 0.05 compared to G1 tumors; vimentin: 
*p < 0.05 compared with G1 tumors **p < 0.01 compared to G1 tumors, 
with invasions in myometrium < ½, with stage I.
Expression of the studied markers was signifi-
cantly reduced in stage III EC compared with these 
at stages І and ІІ of the disease.
The direction of changes in β-catenin expression 
in the investigated tumors of the endometrium was 
different, namely, lower than Me in tumors of mode rate 
and low differentiation grades and neoplasms with deep 
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invasion into myometrium, and in patients with stage 
I of the tumor process. 
In high-proliferating tumors, the expression 
of E-cadherin was significantly increased, and β-catenin 
tended to decrease compared to those in tumors with 
low PI. Instead, the expression of vimentin practically 
did not depend on PI index.
Taking into account the available literature, according 
to which the detection of vimentin in epithelial tumors 
is one of the characteristics of EMT and the absence 
or low expression of this protein is more common in se-
rous carcinoma of the endometrium [9, 10], we have 
compared clinical morphological and molecular-bio-
logical indices in tumors of patients with high expression 
of vimentin and with vimentin-negative EC (Table 2).
The analysis of the data showed that in the group of vi-
mentin-negative EC, tumors of low differentiation grade 
and deep invasion in myometrium prevailed compared 
with the cases with high expression of vimentin. In addi-
tion, in the tumors with high expression of vimentin, a sig-
nificant decrease in the expression of E-cadherin was 
observed as well as the number of cells expressing E-
cadherin in the cytoplasm (78.9 ± 3.6%) and β-catenin — 
with cytoplasmic-nuclear localization (73.7 ± 3.2%) 
compared to these indices in vimentin-negative tumors 
(respectively, 45.4 ± 4.2%, p < 0.001 and 54.5 ± 2.6%, p 
< 0.005). It was found that in EC without E-cadherin ex-
pression, high expression of vimentin (76.9 ± 6.8 points) 
was observed, which was higher than in tumors with high 
expression of E-cadherin (56.1 ± 4.6 points) .
In tumors without vimentin expression, a high corre-
lation was found between the expression of E-cadherin 
and β-catenin (r = 0.7, p < 0.05), which was absent 
in the vimentin-positive tumors suggesting the shift 
in E-cadherin/β-catenin ratio.
It should be noted that the proliferative potential 
in vimentin-negative tumors and tumors with high ex-
pression of vimentin was higher than Me. That is, most 
EC are highly proliferating tumors.
DISCUSSION
The study revealed a significant EC heterogeneity 
by clinical and morphological characteristics, and such 
molecular characteristics as the expression of markers 
providing intercellular adhesion and associated with 
EMT. It is known that tumor progression is associated 
with the acquisition of invasive and metastatic proper-
ties by tumor cells. The latter arise as a result of pro-
tein-protein and protein-DNA interactions in a number 
of signaling cascades, which leads to a decrease 
in intercellular adhesion, which determines the EMT 
and accelerates the growth rate of the tumor [19].
Table 2. Comparative study of clinical-morphological and molecular-biological indices in EC related to the level of vimentin expression
Expression 
of vimentin, 
points 
Number of cases, % Expression of markers, M ± m, points
PI, %Differentiation grade Depth of tumor invasion into myometrium Е-cadherin β-catenin 
G1 G2 G3 < ½ > ½
> Ме (41.6)
(n = 25) 12.0 64.0 24.0 48.0 52.0 63.6 ± 9.4* 151.0 ± 9.4 27.6 ± 2.7
0
(n = 14) 0 35.7 64.3 21.4 78.6 98.8 ± 7.9 160.5 ± 9.5 28.9 ± 3.7
Note: * p < 0.05 compared with the vimentin-negative tumors. 
Fig. 1. Expression of E-cadherin and vimentin in the mod-
erately differentiated and β-catenin in highly differentiated 
EC, × 400: a — diffuse membrane-cytoplasmic expression 
of E-cadherin; b — diffuse membrane-cytoplasmic expression 
of β-catenin; c — expression of vimentin. IHC, stained with 
Mayer’s hematoxylin
a
b
c
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According to current data, one of the causes of EMT 
may be a hormonal imbalance, in particular a decrease 
in the progesterone content. For example, van der Horst 
et al. [23] showed that progesterone stimulates the 
activity of intratumoral T-lymphocytes and inhibits the 
Wnt/β-catenin pathway associated with EMT. It is pos-
sible that, as was shown in our previous studies, the low 
level of progesterone in the peripheral blood of EC pa-
tients, along with the low expression of progesterone 
receptors in tumors and the increase in the number of in-
tratumoral FOXR3 lymphocytes in low-differentiated EC, 
created conditions for EMT, which led to a deep invasion 
of myometrium [24–26]. In fact, in some EC samples 
under study, EMT-associated changes (low or no ex-
pression of E-cadherin, translocation of E-cadherin 
into the cytoplasm, and β-catenin — into the nucleus) 
may be supposed, which is consistent with the literature 
data [13–15, 27, 28].
These translocations of E-cadherin and β-catenin can 
occur during activation of various signaling cascades 
(TGFβ, FGF and Wnt), and due to disorders in the func-
tioning of the genes of CDH1, CTNND1 or genes that pro-
vide degradation of β-catenin (e.g., APC gene) [13, 14]. 
In a nucleus, a transcriptional complex formed between 
β-catenin and T-cell- and lymphoid factors (TCF LEF) 
activates the expression of a number of target genes, 
including the C-MYC, CCND1, VEGF, Axin-2, Snail, VIM 
and others, which leads to an increase in proliferative 
and angiogenic potential of malignant neoplasms, which 
is accompanied by the appearance of a marker of the 
mesenchymal tissues vimentin [13, 14, 16, 19].
Increased expression of vimentin associated with 
an increase in the migration and invasive properties 
of cancer cells was noted by other researchers in malig-
nant neoplasms and cell lines derived from the tumors 
of other genesis [11, 29]. The presence of such a link has 
been shown in cell lines and surgical samples of breast 
tumors with low estrogen receptor levels. The authors 
emphasize that the expression of vimentin influences 
the invasive phenotype of cancer cells only in coopera-
tion with other, yet clearly unidentified proteins [30].
Separate attention should be given to the cases 
of EC with high-level expression of E-cadherin and 
β-catenin, and without expression of vimentin. In 64.3% 
of cases, such tumors were characterized by a low dif-
ferentiation grade and in 78.6% of cases — by a deep 
invasion in myometrium. That is, more than 60% of these 
tumors were more aggressive than vimentin-positive 
tumors. It is possible that in vimentin-negative tumors, 
could be present a EGFR-mediated activation of PI3K/
AKT signaling, which is accompanied by an increase in the 
expression of E-cadherin and the formation of tumor cell 
complexes — microembolies with dense intercellular con-
tacts with so-called “collective or chain migration” [12, 14].
Summing up the results obtained, it can be hypothe-
sized that the formation of a more aggressive phenotype 
in the vimentin-negative tumors of the endometrium 
is not due to the reduction of the expression of the mark-
ers of intercellular adhesion E-cadherin and β-catenin, 
but via the changes in the functioning of a number 
of proteins, oncosuppressors p53, р21WAF1/CIP1, р16INK4a 
and others [11, 31, 32].
To confirm our experimental data, a bioinformat-
ics analysis of the VIM mRNA expression was per-
formed [33]. The portal Oncomine, which contains 
data on microarrays and RNA sequencing, was used. 
The evaluation of the array data showed that VIM mRNA 
expression in EC of various differentiation grades and 
the stages at the level of mRNA is similar to our results 
obtained during IHC analysis of vimentin expression.
The level of VIM mRNA expression in moderately 
and low-differentiated EC is reduced in comparison 
with highly differentiated tumors (Fig. 2). 
In addition, it has been shown that VIM expression 
also progressively decreased in tumors of patients with 
stage II and III compared to that in patients with stage I 
(Fig. 3).
Thus, the data of the bioinformatics analysis show 
that the decrease in the expression of vimentin in EC cor-
relates with the aggressiveness of this type of cancer.
In conclusion, our data show that the progres-
sion of the endometrioid carcinoma may occur due 
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Fig. 3. Expression of the VIM gene at the level of mRNA 
in EC carcinomas stages I–IV by FIGO
Lo
g2
 m
ed
ia
n-
ce
nt
er
ed
 ra
tio
              Grade 1 Grade 2 Grade 3
20423 measured genes
Fig. 2. Expression of the VIM gene at the level of mRNA 
in EC of varying differentiation grades (Grade 1–3) 
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to various molecular changes, in particular, decreased 
expression of E-cadherin and β-catenin proteins, 
and high expression of the marker of mesenchymal 
tissues — vimentin, or in the absence of vimentin ex-
pression, with the involvement of other mechanisms 
of regulating proliferative and metastatic potential.
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